Potential Misinterpretation of Treatment Effects Due to Use of Odds Ratios and Logistic Regression in Randomized Controlled Trials by Knol, Mirjam J. et al.
Potential Misinterpretation of Treatment Effects Due to
Use of Odds Ratios and Logistic Regression in
Randomized Controlled Trials
Mirjam J. Knol*, Ruben G. Duijnhoven, Diederick E. Grobbee, Karel G. M. Moons, Rolf H. H. Groenwold
Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands
Abstract
Background: In randomized controlled trials (RCTs), the odds ratio (OR) can substantially overestimate the risk ratio (RR) if
the incidence of the outcome is over 10%. This study determined the frequency of use of ORs, the frequency of
overestimation of the OR as compared with its accompanying RR in published RCTs, and we assessed how often regression
models that calculate RRs were used.
Methods: We included 288 RCTs published in 2008 in five major general medical journals (Annals of Internal Medicine,
British Medical Journal, Journal of the American Medical Association, Lancet, New England Journal of Medicine). If an OR was
reported, we calculated the corresponding RR, and we calculated the percentage of overestimation by using the formula
ln(OR){ln(RR)
ln(RR)
 100.
Results: Of 193 RCTs with a dichotomous primary outcome, 24 (12.4%) presented a crude and/or adjusted OR for the
primary outcome. In five RCTs (2.6%), the OR differed more than 100% from its accompanying RR on the log scale. Forty-one
of all included RCTs (n=288; 14.2%) presented ORs for other outcomes, or for subgroup analyses. Nineteen of these RCTs
(6.6%) had at least one OR that deviated more than 100% from its accompanying RR on the log scale. Of 53 RCTs that
adjusted for baseline variables, 15 used logistic regression. Alternative methods to estimate RRs were only used in four RCTs.
Conclusion: ORs and logistic regression are often used in RCTs and in many articles the OR did not approximate the RR.
Although the authors did not explicitly misinterpret these ORs as RRs, misinterpretation by readers can seriously affect
treatment decisions and policy making.
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Introduction
A randomized controlled trial (RCT) is generally considered the
best approach to estimate treatment benefits. Results of RCTs are
used to make treatment decisions for clinical practice and policy
making. If the outcomeof a RCT is dichotomous, the treatment effect
can be expressed by several effect estimates, e.g. the risk difference,
the risk ratio (RR), the odds ratio (OR), and the hazard ratio which is
used for time-to-event data. The OR is commonly interpreted as a
RR. As long as the incidence of the outcome is not too high, e.g.
below 10%, the OR is a good approximation of the RR. However, if
the incidence is high, the OR can substantially overestimate the RR
[1,2]. In addition, the further away the OR is from 1, the larger the
overestimation. We note that in case-control studies, in contrast to
RCTs and cohort studies, the outcome does not need to be rare for
the OR to approximate the RR in certain situations [3].
As an example of overestimation of the RR by the OR in a RCT,
suppose that 500 patients are treated with drug A and 500 with
placebo. The outcome is survival for 30 days. In the treatment arm
85% of the patients survive 30 days, and in the placebo arm 70% of
the patients survive 30 days. The OR for survival would be 2.4, and
the RR 1.2 (see Table 1). If the OR is interpreted as a RR, the
conclusion would be that patients using drug A have a 2.4 times
higherchanceto survive than patients using placebo,while inreality
patients using drug A have only 1.2 times higher chance of survival
than placebo users. Another well known example is by Schulman
et al. who presented an OR of 0.6 of referral for cardiac
catheterization in blacks as compared with whites, and for women
as compared with men, while the RR was only 0.93 [4,5]. A
newspaper report stated about this research: ‘‘Blacks and women
with chest pain are 40% less likely than whites or men to be referred
by physicians for cardiac catheterization’’, while this was only 7%
[5]. Interpreting ORs as RRs can thus lead to erroneous
conclusions, which could seriously affect treatment decision making.
Researchers often present ORs to quantify the treatment effect
in a RCT, because they have applied logistic regression to adjust
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ratios. However, other multivariable regression models that
directly estimate RRs are available, such as log-binomial
regression [6] and Poisson regression with robust standard errors
[7].
The aim of this study was to investigate the potential for
misinterpretation of treatment effects in a sample of published
RCTs by determining the frequency of use of ORs, and the
frequency of overestimation of the OR as compared with its
accompanying RR. In addition, we assessed how often regression
models that directly calculate RRs were used. In the end, we give
three illustrative examples from the included RCTs to highlight
that misinterpretation of odds ratios can occur and that we can do
better in analyzing trials.
Methods
Selection of articles
We included all RCTs published in 2008 in five major general
medical journals (Annals of Internal Medicine, British Medical
Journal, Journal of the American Medical Association, Lancet,
and New England Journal of Medicine). We identified these RCTs
in a search on Pubmed combining the journal names with the
publication type ‘randomized controlled trial’ and publication date
‘2008’. RCTs that were published online in 2008 but on paper in
2009 were excluded. Furthermore, letters and studies that were
not RCTs were excluded.
Data extraction
A standardized data extraction form was used to assess the
articles. Two reviewers (MK and RG) independently extracted the
data, each of them assessing half of the articles. We extracted
general items including journal name, number of subjects, type of
treatment, and the scale of the primary outcome (continuous,
dichotomous, ordinal, count). For articles with a dichotomous
primary outcome we extracted the crude measure of effect of the
primary outcome (e.g. OR, RR), the analysis that was used to
adjust for baseline variables if applicable (e.g. logistic regression,
Cox regression), and the adjusted measure of effect of the primary
outcome if applicable (e.g. OR, hazard ratio). In addition, we
extracted whether any other OR was mentioned in the articles, for
example for secondary outcomes or subgroup analyses. If ORs
were presented, we also extracted the incidence of the outcome in
the non-exposed group to calculate the amount of overestimation
of the OR as compared with the RR (see below). If RCTs
performed stratified randomization and adjusted for these
stratification factors in the analysis, we did not score this as
adjustment for baseline variables. We did not extract any ORs that
were part of a prognostic prediction model made with the RCT
data, because in this article we were interested in estimation of
treatment effects.
Data analysis
Frequencies and summary statistics of the extracted items were
presented. If an OR was reported and the incidence in the non-
exposed group was known, we calculated the corresponding RR to
estimate the extent of overestimation of the OR, using the
formula: RR~
OR
(1{P0)z(P0  OR)
, where P0 is the incidence of
the outcome in the non-exposed group [2]. Subsequently, we
calculated the percentage difference between the presented OR
and calculated RR by using the formula:
ln(OR){ln(RR)
ln(RR)
 100.
The formula to calculate RRs based on the OR and the incidence
of the outcome in the non-exposed has been criticized, especially
for adjusted ORs [8,9]. The RR calculated using this formula
gives some bias away from the null, and this increases with
increasing outcome incidence and effect estimate. This means that
we slightly underestimate the percentage difference between the
presented OR and calculated RR.
Results
Characteristics of the included RCTs
Our primary search yielded 349 articles. We excluded 8 articles
that were published online in 2008 but on paper in 2009, 31
letters, and 22 articles that were not RCTs. This resulted in 288
RCTs that were published in Annals of Internal Medicine (n=16,
5.6%), BMJ (n=45, 15.6%), JAMA (n=51, 17.7%), Lancet
(n=80, 27.8%), and New England Journal of Medicine (n=96,
33.3%). Most RCTs investigated the effect of drugs (64.2%). The
median number of patients included in the RCTs was 663 with a
range of 13 to 31,290. The majority of the RCTs had a
dichotomous primary outcome (n=193, 67.0%), while 30.6% and
2.4% had a continuous and other outcome (e.g., count, ordinal),
respectively.
Use of ORs for primary outcome
Of the 193 studies with a dichotomous primary outcome, the
majority presented hazard ratios because the outcome was time-
to-event (Figure 1). RRs were also often presented as crude effect
estimates (19.2%) but less as adjusted effect estimates (11.3%). Ten
RCTs only presented a crude OR, 7 only presented an adjusted
OR, and 7 presented both a crude and adjusted OR, so a total of
24 RCTs (12.4%) presented a crude and/or adjusted OR for the
primary outcome. Figure 2 presents the crude and adjusted ORs
and their accompanying crude and adjusted RRs calculated using
the formula above (for three ORs the accompanying RR could not
be calculated because the incidence of the outcome was not given
(16) and because the value of the adjusted OR was not given
(26)). In six RCTs (3.1%) the OR differed between 50% and
100% from the RR on the log scale, and in five RCTs (2.6%) the
OR differed more than 100% from the RR on the log scale (e.g.
OR=8.0, RR=2.0). In the latter five RCTs, the overall incidence
of the outcome ranged from 53–64%.
None of the 24 RCTs that presented ORs explicitly interpreted
the OR as a RR, for example stating that the risk of the outcome
was doubled in the treatment group as compared to the control
Table 1. Suppose that 500 patients are treated with drug A
and 500 with placebo.
Survival after 30 days
Yes (N, %) No (N, %) Total
Drug A 425 (85%) 75 (15%) 500
Placebo 350 (70%) 150 (30%) 500
Total 775 225 1000
The outcome is survival for 30 days. In the treatment arm 85% of the patients
survive 30 days, and in the placebo arm 70% of the patients survive 30 days.
The two-by-two table looks as above.
The odds ratio is calculated as the ratio of the odds of treatment in the patients
who survived (425/350=1.21) and the odds of treatment in the patient who did
not survive (75/150=0.50), resulting in an odds ratio of 1.21/0.50=2.43. One
could also calculate the cross-product of the table: (425*150)/(350*75)=2.43.
The risk ratio is calculated as the ratio of the risk of survival in the treatment
group (425/500=0.85) and the risk of survival in the placebo group (350/
500=0.70), resulting in a risk ratio of 0.85/0.70=1.21.
doi:10.1371/journal.pone.0021248.t001
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risk of the outcome was lower/greater while reporting an OR
between brackets after this statement, suggesting that the OR
could be interpreted as a RR, which in one RCT was obviously
not the case (OR=13.40, RR=3.66). Furthermore, none of the
RCTs that presented ORs warned the reader that the OR could
not be interpreted as a RR.
Use of other ORs than for primary outcome
Forty-one of all included RCTs (14.2%) presented ORs for
other outcomes than the primary outcome, or for subgroup
analyses. Nineteen RCTs (6.6%) had at least one OR that deviated
more than 100% from its accompanying RR on the log scale (e.g.
OR=5.4, RR=1.2; OR=0.49, RR=0.94) (Figure 3). The ORs
that showed more than 100% deviation had accompanying overall
incidences of the outcome from 50 to 92%.
Use of alternative methods
Among the 193 RCTs with a dichotomous primary outcome,
53 (27.5%) adjusted for baseline variables. Twenty-six RCTs
(13.5%) used Cox regression because the outcome was time-to-
event. Fifteen RCTs (7.8%) used logistic regression. Alternative
methods for logistic regression to directly estimate RRs were only
used in four RCTs (2.1%): two used Poisson regression with a
robust standard error, one used log-binomial regression and one
used the Mantel-Haenszel procedure. Three RCTs used other
methods including negative binomial regression, generalized linear
mixed model with a log link, and generalized estimating equations,
and in five RCTs the method for adjustment was unclear.
Illustrative examples
From the included RCTs we took three illustrative examples to
highlight that misinterpretation of ORs can occur and that we can
do better in analyzing trials.
Example 1. Morley et al. [10] studied whether nasal
continuous positive airway pressure (CPAP), rather than
intubation and ventilation, shortly after birth reduces the rate of
death or bronchopulmonary dysplasia in very preterm infants. In
Table 2 and Table 3 of the original article, the authors present
many ORs for different outcomes and subgroups. Most outcomes
that were studied were common, e.g. the primary outcome death
or oxygen treatment at 36 weeks gestational age occurred in
36.4% of the infants. One of the most striking examples of large
deviation between OR and RR in this study was for the outcome
death, oxygen treatment, or respiratory support at 28 days of age
in the subgroup with infants of 25 or 26 weeks gestation (see Table
3 in original article). In infants receiving CPAP the outcome
occurred in 89.0% and in infants receiving intubation and
ventilation the outcome occurred in 94.3%, resulting in an OR
Figure 1. Crude effect measures presented in 193 RCTs that had a dichotomous primary outcome, and adjusted effect measures
presented in 53 RCTs that had a dichotomous primary outcome and adjusted for baseline variables (OR=odds ratio, RR=risk ratio,
HR=hazard ratio, RD=risk difference). * Other includes presentation of only p-values or only percentages, or no crude measure presented.
doi:10.1371/journal.pone.0021248.g001
Figure 2. ORs and their accompanying RRs for the primary
outcome in 16 RCTs (crude estimate) and 12 RCTs (adjusted
estimate). Dotted line represents the points where the OR and RR are
the same.
doi:10.1371/journal.pone.0021248.g002
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only 0.94 (95% CI: 0.87–1.03). Readers misinterpreting the OR as
a RR could conclude that infants on CPAP have a 51% reduced
risk of the outcome, while in reality this is only 6%.
Example 2. Wheeler et al. [11] studied whether expression of
drug concentration as a ratio (1 ml of a 1:1000 solution) instead of
mass concentration (1 mg in 1 ml) on epinephrine ampules caused
dosing errors. In the ratio group 11 of the 14 doctors made a
dosing error and in the mass concentration group 3 of the 14
doctors made a dosing error. The authors presented an OR: 13.4
(95% CI: 2.2–81.7). However, the corresponding RR is only 3.7
(95% CI: 1.3–10.4).
Example 3. Smolen et al. [12] studied the effect of
tocilizumab on 20% improvement of signs and symptoms of
rheumatoid arthritis. At 24 weeks, response was higher in patients
receiving tocilizumab 8 mg/kg (120/205=59%) than in patients
receiving placebo (54/204=26%). The authors presented an OR
adjusted for region of 4.0 (95% CI: 2.6–6.1). However, using the
formula RR~
OR
(1{P0)z(P0  OR)
, the corresponding RR is only
4:0
(1{0:26)z(0:26  4:0)
~2:2. Because the outcome in this study
is common, the OR and RR deviate substantially. If a reader
interprets this OR as a RR, he would conclude that patients taking
tocilizumab 8 mg/kg have a four times higher probability of
having a good response than patients taking placebo, while in
reality this probability is only 2.2 times higher.
Discussion
This review showed that, despite its difficult interpretation, the
OR is a popular effect measure in RCTs as one-in-eight RCTs
with a dichotomous outcome presented an OR for the primary
outcome, and one-in-seven of all RCTs presented any OR.
Moreover, the OR often overestimated the RR by more than 20%
on the log scale. Furthermore, after Cox regression, logistic
regression was the most often used method to perform baseline
adjustment in RCTs with dichotomous outcomes. Alternative
models to calculate RRs were almost never used.
Although the OR can seriously overestimate the RR, we found
that it is still often estimated in RCTs, even for crude analyses. A
reason may be that an OR has some mathematical advantages
over a RR, including its symmetry with respect to ‘successes’ and
‘failures’ and the fact that the OR may assume values unrestricted
between zero and infinity [13]. In addition, the use of ORs itself is
not wrong as long as the interpretation is correct, i.e. in the case of
a RCT, the odds for the outcome in the treated group (over a
certain time period) as compared with the odds for the outcome in
the control group. We found that none of the authors explicitly
interpreted the OR as RR. However, policy makers or the media
can easily misinterpret ORs as RRs, the latter being nicely
illustrated by Schwartz et al [5]. Our survey showed that
substantial overestimation was present in one third (for primary
outcomes) to two thirds (for secondary outcomes or subgroup
analyses) of RCTs that present ORs, potentially leading to
misinterpretation of results.
Although various alternatives for logistic regression are
available, apparently they are not used for adjustment for
covariables in RCTs. There are several possible reasons for this.
First, it may not be known to authors of clinical papers that the
OR can overestimate the RR. This knowledge could be enhanced
by education and publishing articles on this issue in clinical papers.
Second, authors are probably more familiar with logistic
regression and do not know that there are alternative methods
to estimate adjusted RRs. This could be partly due to the fact that
most literature on the methods and use of these alternative
methods is published in epidemiology journals rather than clinical
journals. Third, from a statistical point of view logistic regression is
convenient for dichotomous outcomes as the predicted probabil-
ities are restricted between 0 and 1. However, simulation studies
have shown that alternative models behave well with regard to bias
and coverage of the 95% confidence interval [9,14] and seem not
to be influenced by possible misspecification of the model. Further
research should be done to assess whether these positive results
apply to all situations and datasets. All widely used statistical
software packages have the possibility to fit models such as Poisson
regression with robust standard errors and log-binomial regression
[15,16], which should therefore not be a barrier to use these
models. The use of alternative models could be increased by
publication of papers on methods and applications of these models
in clinical journals. Also reviewers and editors of clinical journals
should be aware of the possibilities to use alternative models.
Lumley et al. and McNutt et al. nicely summarized several
methods and showed how to apply the methods [9,15].
Our study was based on articles published in leading medical
journals and our results may therefore not be applicable to RCTs
published in less prominent journals. Other studies are needed to
investigate if there are certain medical specialties that are at a
higher risk for misinterpretation of results due to the use of ORs.
Despite the fact that we included a large number of RCTs in our
study, we ended up with a relatively low number of RCTs that had
a dichotomous outcome and did not analyze their data as time-to-
event. Our study should be repeated in a larger sample to get more
robust results. We may have missed some RCTs in our Pubmed
search. However, there is no reason to assume that we selectively
missed particular RCTs so this will most likely not have influenced
our results. We estimated the extent of overestimation of the OR
using the formula of Zhang and Yu [2]. The RR calculated using
this formula gives some bias away from the null [8,9], and this
increases with increasing outcome incidence and effect estimate.
This means that we slightly underestimated the percentage
difference between the presented OR and calculated RR. So the
extent of overestimation of the RR by the OR may even be greater
than we presented. In our study we focused on the misinterpre-
tation of the OR. However, also hazard ratios, which we found are
Figure 3. ORs and their accompanying RRs for other outcomes
or subgroup analyses in 41 RCTs. Dotted line represents the points
where the OR and RR are the same; other lines represent 20%, 50% and
100% difference between OR and RR.
doi:10.1371/journal.pone.0021248.g003
Use of Odds Ratios in RCTs
PLoS ONE | www.plosone.org 4 June 2011 | Volume 6 | Issue 6 | e21248commonly used in RCTs, are difficult to interpret and alternatives
to hazard ratios have been proposed [17–20]. Moreover, there is
elaborate discussion on whether relative or absolute measures of
effect are most informative, but this discussion is out of the scope of
this paper.
In conclusion, ORs and logistic regression are often used in
RCTs currently published in high impact journals. In a substantial
number of articles the OR did not adequately approximate the
RR. Misinterpretation of ORs by authors, readers or media can
seriously affect treatment decisions and policy making. Further
research is needed to study the real impact of using ORs on
reader’s interpretation. We recommend presenting RRs rather
than ORs in RCTs, and using alternative models to calculate RRs
directly if adjustment for baseline variables is considered necessary
to avoid misinterpretation by readers, media or policy makers.
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